Public Library of Science
Browse
pbio.3000688.g001.tif (1.04 MB)

UA prevents HFD-induced obesity and hyperglycemia in mice.

Download (1.04 MB)
figure
posted on 2020-03-27, 17:34 authored by Bo Xia, Xiao Chen Shi, Bao Cai Xie, Meng Qing Zhu, Yan Chen, Xin Yi Chu, Guo He Cai, Min Liu, Shi Zhen Yang, Grant A. Mitchell, Wei Jun Pang, Jiang Wei Wu

(A) Schematic diagram of mice treatment. Six pairs of C57BL/6 male mice fed an HFD were treated with 30 mg/kg/day of UA or vehicle by gavage starting from 8 weeks of age for a period of 10 weeks. (B) Body weight time course. (C) Body composition measured by DEXA scan after 7 weeks of treatment. (D) Cumulative food intake. (E) Levels of fecal TG after 10 weeks of treatment. levels of (F) plasma glucose and (G) insulin after 5 h fasting (n = 6). (H) HOMA-IR index. (I) ITT performed after 6 weeks of treatment and (J) the AUC. (K) GTT performed after 8 weeks of treatment and (L) the AUC. (M) Time course of plasma glucose and GIR during the hyperinsulinemic–euglycemic clamp. (N) Whole-body insulin-stimulated glucose uptake. (O) Insulin-stimulated 2-DG uptake in skeletal muscle, BAT, and WAT. (P) Basal and clamp EGP. The underlying data for this figure can be found in S1 Data. AUC, area under the curve; BAT, brown adipose tissue; DEXA, dual-energy X-ray absorptiometry; EGP, endogenous glucose production; GIR, glucose infusion rate; GTT, glucose tolerance test; HFD, high-fat diet; HOMA-IR, homeostasis model assessment-estimated insulin resistance; ITT, insulin tolerance test; TG, triglyceride; UA, urolithin A; WAT, white adipose tissue; 2-DG, 2-deoxyglucose.

History